Abbott has presented two clinical trials data at the EuroPCR 2010 conference supporting Xience V Everolimus Eluting Coronary Stent System. In the Xience V US study of more than 5,000 real-world, complex patients, Xience V demonstrated a low rate of blood clots (stent thrombosis) at one year (0.84% per Academic Research Consortium [ARC] definition of definite/probable stent thrombosis).
In a subset of approximately 1,800 less complex patients (referred to as ‘standard risk’), Xience V demonstrated a one-year stent thrombosis rate of 0.34% per ARC definition of definite/probable stent thrombosis.
Abbott said that the Xience V USA study also showed that stent thrombosis rates remained low even when dual anti-platelet therapy (DAPT) was temporarily or permanently discontinued. In the overall Xience V USA population, patients who interrupted DAPT usage after six months showed a subsequent late stent thrombosis rate of zero percent.
In the subset of standard risk patients, those who interrupted DAPT usage after 30 days also showed a subsequent late stent thrombosis rate of zero percent. DAPT compliance in the Xience V USA study was 79.4% at one year.
James Hermiller, director of Cardiovascular Interventions, St Vincent Hospital in Indianapolis, and principal investigator of the Xience V USA trial, said: “The low stent thrombosis rate demonstrated by Xience V is impressive given the complexity of the patient population included in the Xience V USA trial, and confirms that the stent thrombosis results seen with Xience V in earlier randomized clinical trials are consistent in real-world clinical practice.”